ClearRead +Confirm software receives FDA clearance

Editorial Staff | | Health Imaging | Screening

The FDA has given 510(k) clearance to Riverain Technologies’ ClearRead +Confirm software, which is designed to improve chest x-ray clarity and aid in proper placement of tubes, lines and wires.

ClearRead +Confirm selectively increases contrast and suppresses clavicles and ribs in conventional chest x-ray images that can create obstacles and obscure visibility of feeding, drug delivery and pain management tubes, lines and cardiac wires.

A Georgetown University reader study of 334 chest x-rays found reading time was reduced approximately 19 percent using the software without compromising accuracy, according to Dayton, Ohio-based Riverain Technologies.

Editorial Staff

Related Content

Rising rates of interval breast cancers have experts calling for more risk-based screenings
Rates of breast cancer diagnosis, death expected to climb in coming decades
AI quantifies breast arterial calcifications on mammograms
AI 'not safe' to be implemented as a solo reader for breast cancer screening exams
American College of Radiology announces significant expansion of Lung Cancer Screening Registry
AI beats standard regression models at predicting lung cancer risk

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.